miR Scientific and Leonie Hill Capital Announce Collaboration to Introduce Breakthrough Urine Liquid Biopsy Prostate Cancer Test in Singapore

High demand seen for effective disease management platform for second most common cancerinSingaporeanmen

NEW YORK and SINGAPORE,March 28,2022 --miR Scientific,a New York-basedhealthcare company dedicated to transforming global cancer management,and Leonie HillCapital,a Singapore-based organization focused on large-scale,sophisticated healthcareaccess and distribution,announced today the signing of a collaboration agreement to partner inthe commercial launch of the award-winning miR Sentinel™ Prostate Cancer Test in SingaporeandSoutheastAsia.

The miR Sentinel™ Prostate Cancer Test is a standalone,non-invasive liquid biopsy urine testthat can,from a single urine specimen,accurately detect molecular evidence of prostate cancerand,if cancer is detected,classify the severity,or the risk grade,of the malignancy.Theproprietary high-throughput technology is based on the interrogation of small noncoding RNAs(sncRNAs) extracted from urinary exosomes and was shown in clinical studies to detect andclassify clinically significant prostate cancer with over 90% accuracy.Based on these results,theU.S.Food&DrugAdministrationgranted thetest aBreakthroughDeviceDesignation.

"The commercial appeal and likely demand in Singapore for an easy-to-administer,non-invasiveand highly accurate test that can detect and risk classify prostate cancer is substantial" saidArun Kant,CEO of Leonie Hill Capital. "The high throughput nature of the technology and miR Scientific'sbusiness model that is centered on specimens shipped to a certified central lab for testing easilylendsitself forrapidcommercial deploymentinamarket such asSingapore" hesaid.

In advance of a commercial deployment of the technology in Singapore,the parties agreed towork together to facilitate a local clinical validation study in cooperation with leading localacademic medical institutions.The study will be designed to further establish the performance characteristicsofthemiRSentinel™ ProstateCancer Testinthelocalmarket.

"We are excited to be working with Arun and the LHC team in Singapore" said Sam Salman,co-founder,Chairman and CEO of miR Scientific. "The disease burden of prostate cancer inSingapore is substantial and growing,affecting many. It is the second most common cancer inSingaporean men,and according to the Singapore Cancer Society,one in four patients isdiagnosed with advanced disease with costly and poor outcomes. We hope that the introductionof the miR Sentinel™ Prostate Cancer Test will significantly improve outcomes. Singapore is an established regional hub of medical excellence,known for the willingness of its health system toembrace innovation and improve population health. These factors make Singapore a high priority market for miRScientific'sglobal expansion."

miR Scientific and LHC plan to commence operation of the partnership and introduce the technologyinSingaporeduringthesecond quarterof2022.

AboutmiRScientific

miR Scientific,LLCis a healthcare company committed to transforming global cancermanagement by providing early and highly accurate detection,characterization and monitoringof disease. The Company has developed the miR Disease Management Platform®,aproprietary,non-invasive platform for the effective management of targeted diseases,initiallyfocusedon urologicalcancers.Theplatform powersthemiRSentinel™ ProstateCancerTest,a liquid biopsy urine test that accurately detects,classifies and can monitor prostate cancer based on the interrogation of sncRNAs extracted from non-DRE urinary exosomes. miRScientific is developing interoperable products and services necessary to revolutionize thestandards of care supporting urologic oncology,including prostate,bladder and other urothelialcancers. Such new standards are urgently needed given the prevalence of these cancers andtheir debilitating burden globally. miR Scientific is a majority-owned operating subsidiary ofImpact NRS LLC,headquartered in New York City with operating subsidiaries in Israel,Japan,Canada,andPuertoRico.

AboutLeonieHillCapital

Leonie Hill Capital is a Registered Fund Management Company overseen by a managementteam with more than 60 years of experience across global markets with headquarters inSingapore and representative offices in Switzerland,Japan and the United States,with morethanUSD$2B under management.

Contact:

media@mirscientific.com